Number 5: Sarfaraz K. Niazi, PhD, argues that the FDA can accelerate biosimilar entry by changing guidance under the Biologics Price Competition and Innovation Act (BPCIA) without needing ...

Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating ...

Biosimilars promise cost savings and improved patient access in Latin America, yet face significant regulatory and ...

Number 5: Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...

Government price negotiations under the Inflation Reduction Act may hinder biosimilar development, impacting drug costs and ...

Biosimilars face a potential void as biologics lose exclusivity, prompting urgent calls for policy reform and enhanced ...

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges ...

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...

Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the ...